Network Meta-Analysis Comparing Efficacy and Safety Outcomes of Atogepant, Rimegepant, and Galcanezumab in Patients with Episodic Migraine After Including CHALLENGE-MIG Trial (P9-12.007)
Network meta-analysis (NMA) of atogepant (Ato) relative to rimegepant (Rime) and galcanezumab (Galc) after inclusion of the CHALLENGE-MIG trial for efficacy and safety outcomes in episodic migraine (EM) patients.
Authors
- Rashmi B. Halker Singh (ORCID: https://orcid.org/0000-0002-4280-4440)
- Tanya R. Bilchik
- Pranav Gandhi (ORCID: https://orcid.org/0009-0008-8317-7712)
- Stephanie J. Nahas (ORCID: https://orcid.org/0000-0001-8846-8393)
- Jessica Ailani (ORCID: https://orcid.org/0000-0001-8106-4927)
- Amber Trujillo Lalla (ORCID: https://orcid.org/0000-0003-4267-1374)
- Kari Kelton (ORCID: https://orcid.org/0000-0002-2692-4899)
- Cristiano Piron
- David A. Rowe (ORCID: https://orcid.org/0000-0001-5249-9008)
- Peter McAllister (ORCID: https://orcid.org/0000-0003-4965-7700)
Institutions
- Thomas Jefferson University (US)
- WinnMed (US)
- AbbVie (United States) (US)
- Yale University (US)
- Medical Decision Modeling (United States) (US)
- New England Institute for Neurology and Headache (US)
- AbbVie (Japan)
- MedStar Health (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000210714
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00